Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

James R. Hocker, Subrato J. Deb, Min Li, Megan R. Lerner, Stan A. Lightfoot, Aurelien A. Quillet, R. Jane Hanas, Matthew Reinersman, Jess L Thompson, Nicole T. Vu, Thomas C. Kupiec, Daniel J. Brackett, Marvin D. Peyton, Stephen M. Dubinett, Harold M. Burkhart, Russell G. Postier, Jay S. Hanas

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalCancer Investigation
DOIs
StateAccepted/In press - Sep 22 2017
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Phenotype
Lung Neoplasms
Serum
Tandem Mass Spectrometry
Computational Biology
Squamous Cell Carcinoma
Adenocarcinoma
Lymphocytes
Peptides
Proteins

Keywords

  •  

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hocker, J. R., Deb, S. J., Li, M., Lerner, M. R., Lightfoot, S. A., Quillet, A. A., ... Hanas, J. S. (Accepted/In press). Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. Cancer Investigation, 1-13. https://doi.org/10.1080/07357907.2017.1373120

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. / Hocker, James R.; Deb, Subrato J.; Li, Min; Lerner, Megan R.; Lightfoot, Stan A.; Quillet, Aurelien A.; Hanas, R. Jane; Reinersman, Matthew; Thompson, Jess L; Vu, Nicole T.; Kupiec, Thomas C.; Brackett, Daniel J.; Peyton, Marvin D.; Dubinett, Stephen M.; Burkhart, Harold M.; Postier, Russell G.; Hanas, Jay S.

In: Cancer Investigation, 22.09.2017, p. 1-13.

Research output: Contribution to journalArticle

Hocker, JR, Deb, SJ, Li, M, Lerner, MR, Lightfoot, SA, Quillet, AA, Hanas, RJ, Reinersman, M, Thompson, JL, Vu, NT, Kupiec, TC, Brackett, DJ, Peyton, MD, Dubinett, SM, Burkhart, HM, Postier, RG & Hanas, JS 2017, 'Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients', Cancer Investigation, pp. 1-13. https://doi.org/10.1080/07357907.2017.1373120
Hocker, James R. ; Deb, Subrato J. ; Li, Min ; Lerner, Megan R. ; Lightfoot, Stan A. ; Quillet, Aurelien A. ; Hanas, R. Jane ; Reinersman, Matthew ; Thompson, Jess L ; Vu, Nicole T. ; Kupiec, Thomas C. ; Brackett, Daniel J. ; Peyton, Marvin D. ; Dubinett, Stephen M. ; Burkhart, Harold M. ; Postier, Russell G. ; Hanas, Jay S. / Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. In: Cancer Investigation. 2017 ; pp. 1-13.
@article{57ec2da44c2d4707bbab82b5f75a659b,
title = "Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients",
abstract = "A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.",
keywords = " ",
author = "Hocker, {James R.} and Deb, {Subrato J.} and Min Li and Lerner, {Megan R.} and Lightfoot, {Stan A.} and Quillet, {Aurelien A.} and Hanas, {R. Jane} and Matthew Reinersman and Thompson, {Jess L} and Vu, {Nicole T.} and Kupiec, {Thomas C.} and Brackett, {Daniel J.} and Peyton, {Marvin D.} and Dubinett, {Stephen M.} and Burkhart, {Harold M.} and Postier, {Russell G.} and Hanas, {Jay S.}",
year = "2017",
month = "9",
day = "22",
doi = "10.1080/07357907.2017.1373120",
language = "English (US)",
pages = "1--13",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

AU - Hocker, James R.

AU - Deb, Subrato J.

AU - Li, Min

AU - Lerner, Megan R.

AU - Lightfoot, Stan A.

AU - Quillet, Aurelien A.

AU - Hanas, R. Jane

AU - Reinersman, Matthew

AU - Thompson, Jess L

AU - Vu, Nicole T.

AU - Kupiec, Thomas C.

AU - Brackett, Daniel J.

AU - Peyton, Marvin D.

AU - Dubinett, Stephen M.

AU - Burkhart, Harold M.

AU - Postier, Russell G.

AU - Hanas, Jay S.

PY - 2017/9/22

Y1 - 2017/9/22

N2 - A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

AB - A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

KW -  

UR - http://www.scopus.com/inward/record.url?scp=85029906670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029906670&partnerID=8YFLogxK

U2 - 10.1080/07357907.2017.1373120

DO - 10.1080/07357907.2017.1373120

M3 - Article

C2 - 28949774

AN - SCOPUS:85029906670

SP - 1

EP - 13

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

ER -